speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing.

Bibliographic Details
Title: speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing.
Authors: Castellanos-Rueda, Rocío, Di Roberto, Raphaël B., Bieberich, Florian, Schlatter, Fabrice S., Palianina, Darya, Nguyen, Oanh T. P., Kapetanovic, Edo, Läubli, Heinz, Hierlemann, Andreas, Khanna, Nina, Reddy, Sai T.
Source: Nature Communications; 11/2/2022, Vol. 13 Issue 1, p1-16, 16p
Subject Terms: CELL communication, TUMOR-infiltrating immune cells, CHIMERIC antigen receptors, T cells, HIGH throughput screening (Drug development), RNA sequencing, CALCIUM-sensing receptors
Abstract: Chimeric antigen receptors (CARs) consist of an antigen-binding region fused to intracellular signaling domains, enabling customized T cell responses against targets. Despite their major role in T cell activation, effector function and persistence, only a small set of immune signaling domains have been explored. Here we present speedingCARs, an integrated method for engineering CAR T cells via signaling domain shuffling and pooled functional screening. Leveraging the inherent modularity of natural signaling domains, we generate a library of 180 unique CAR variants genomically integrated into primary human T cells by CRISPR-Cas9. In vitro tumor cell co-culture, followed by single-cell RNA sequencing (scRNA-seq) and single-cell CAR sequencing (scCAR-seq), enables high-throughput screening for identifying several variants with tumor killing properties and T cell phenotypes markedly different from standard CARs. Mapping of the CAR scRNA-seq data onto that of tumor infiltrating lymphocytes further helps guide the selection of variants. These results thus help expand the CAR signaling domain combination space, and supports speedingCARs as a tool for the engineering of CARs for potential therapeutic development. Chimeric antigen receptors (CAR) are a promising option for cell-based immunotherapy for cancer and other immune diseases. Here the authors develop speedingCARs, an integrated CAR design and screening platform based on modular signaling domain shuffling and single cell transcriptomic analyses, and test its potential for identifying and validating novel CAR designs. [ABSTRACT FROM AUTHOR]
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.